Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E21.91 EPS (ttm)10.22 Insider Own0.10% Shs Outstand148.00M Perf Week-7.81%
Market Cap33.57B Forward P/E11.82 EPS next Y18.94 Insider Trans-7.05% Shs Float145.87M Perf Month-19.91%
Income1.55B PEG- EPS next Q4.61 Inst Own86.60% Short Float1.41% Perf Quarter-32.88%
Sales11.10B P/S3.02 EPS this Y-21.10% Inst Trans-1.20% Short Ratio1.78 Perf Half Y-43.43%
Book/sh70.47 P/B3.18 EPS next Y-1.26% ROA6.40% Target Price345.39 Perf Year-8.26%
Cash/sh19.71 P/C11.36 EPS next 5Y-6.50% ROE14.50% 52W Range224.46 - 468.55 Perf YTD-8.55%
Dividend- P/FCF13.89 EPS past 5Y10.10% ROI19.60% 52W High-52.21% Beta0.44
Dividend %- Quick Ratio1.40 Sales past 5Y4.50% Gross Margin82.50% 52W Low-0.24% ATR8.00
Employees9100 Current Ratio1.70 Sales Q/Q-17.70% Oper. Margin17.30% RSI (14)17.98 Volatility3.89% 2.99%
OptionableYes Debt/Eq0.70 EPS Q/Q-50.40% Profit Margin13.90% Rel Volume1.13 Prev Close228.52
ShortableYes LT Debt/Eq0.60 EarningsOct 20 BMO Payout0.00% Avg Volume1.15M Price223.92
Recom2.30 SMA20-12.88% SMA50-16.96% SMA200-24.95% Volume1,304,314 Change-2.01%
Nov-19-21Initiated BMO Capital Markets Outperform $315
Sep-23-21Initiated Needham Buy $400
Jun-18-21Upgrade Piper Sandler Neutral → Overweight $384 → $450
Jun-14-21Reiterated Truist Buy $458 → $647
Jun-11-21Upgrade Bernstein Mkt Perform → Outperform $500
Jun-10-21Upgrade UBS Neutral → Buy
Jun-08-21Upgrade William Blair Mkt Perform → Outperform
Jun-08-21Upgrade Robert W. Baird Underperform → Neutral $216 → $382
Jun-08-21Upgrade Citigroup Sell → Neutral $200 → $440
Jun-08-21Upgrade Atlantic Equities Underweight → Neutral $415
Jun-08-21Reiterated Stifel Buy $346 → $446
Jun-08-21Reiterated RBC Capital Mkts Sector Perform $259 → $400
Jun-08-21Reiterated Morgan Stanley Overweight $343 → $455
Jun-08-21Reiterated Jefferies Buy $450 → $500
Jun-08-21Reiterated H.C. Wainwright Buy $305 → $452
Jun-08-21Reiterated Barclays Equal Weight $265 → $395
Jun-07-21Upgrade Raymond James Underperform → Mkt Perform
Jun-07-21Upgrade Cowen Market Perform → Outperform $225 → $450
Jun-07-21Upgrade BofA Securities Underperform → Neutral $235 → $400
Feb-05-21Downgrade DZ Bank Buy → Hold $264
Dec-03-21 05:11PM  
06:15AM  
03:15AM  
02:51AM  
Dec-02-21 05:37PM  
06:14AM  
06:00AM  
Dec-01-21 09:01AM  
06:30AM  
Nov-30-21 10:31AM  
Nov-28-21 08:46AM  
Nov-26-21 01:29PM  
Nov-24-21 11:21AM  
Nov-23-21 01:36PM  
Nov-19-21 11:30AM  
Nov-18-21 10:36AM  
08:43AM  
Nov-17-21 04:04PM  
12:07PM  
10:59AM  
10:53AM  
10:07AM  
07:51AM  
07:30AM  
06:46AM  
03:45AM  
03:23AM  
03:01AM  
Nov-16-21 12:42PM  
11:31AM  
10:31AM  
09:58AM  
09:20AM  
Nov-15-21 08:31PM  
08:24PM  
07:44PM  
02:36PM  
02:10PM  
07:30AM  
Nov-12-21 04:46PM  
10:53AM  
08:13AM  
07:40AM  
03:00AM  
01:23AM  
Nov-11-21 05:10PM  
05:10PM  
12:58PM  
12:00PM  
11:20AM  
09:31AM  
Nov-10-21 02:57PM  
12:37PM  
06:08AM  
06:00AM  
Nov-09-21 02:31PM  
12:44PM  
09:51AM  
Nov-04-21 03:32PM  
11:11AM  
08:29AM  
07:02AM  
Nov-03-21 12:47PM  
07:30AM  
Nov-02-21 08:00AM  
Nov-01-21 05:32PM  
12:08PM  
Oct-29-21 11:30AM  
Oct-28-21 10:00AM  
06:30AM  
Oct-27-21 07:25AM  
Oct-26-21 09:00PM  
04:26PM  
11:47AM  
11:32AM  
08:02AM  
Oct-23-21 07:55AM  
06:08AM  
Oct-22-21 05:51PM  
10:06AM  
Oct-21-21 12:33PM  
12:00PM  
11:00AM  
10:39AM  
09:52AM  
07:01AM  
Oct-20-21 04:22PM  
04:11PM  
01:23PM  
01:00PM  
11:52AM  
11:38AM  
10:46AM  
10:35AM  
10:34AM  
10:21AM  
08:25AM  
08:17AM  
07:53AM  
07:49AM  
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCDONNELL MICHAEL REVP, Chief Financial OfficerSep 01Option Exercise338.246,0052,031,1314,864Sep 03 04:08 PM
Sandrock AlfredHead of Research & DevelopmentJun 07Sale440.007,6723,375,68010,169Jun 09 07:05 PM
Guindo ChirfiHead of Glob Prod Strat & ComJun 07Sale440.003,0871,358,2802,919Jun 09 07:04 PM
Posner Brian SDirectorJun 04Sale274.1736098,7017,400Jun 07 07:02 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 12Option Exercise0.004,454019,715Feb 17 05:01 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.0016,289060,194Feb 17 05:03 PM
Kramer RobinSVP, Chief Accounting OfficerFeb 12Option Exercise0.003330706Feb 17 04:59 PM
Guindo ChirfiEVP Glob. Prod Strat and CommFeb 12Option Exercise0.003,15606,946Feb 17 04:58 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.002,92309,288Feb 17 04:56 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.001,57304,765Feb 17 04:54 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 12Option Exercise0.004,355043,509Feb 17 04:52 PM
Mantas Jesus BDirectorFeb 09Buy267.00898239,7662,943Feb 10 04:31 PM